Maitake MD-Fraction Mushroom Extract Therapy

Therapy | Treatment

Maitake MD-fraction Mushroom
Extract Therapy

To assist in the treatment of cancer, HIV, Hepatitis and immune system diseases.

Maitake MD-fractionMaitake ResearchBuy Maitake MD-fraction |

Maitake: King of Mushrooms

Maitake (scientific name Grifola frondosa) is indigenous to the northeastern part of Japan. In Japan, Maitake can grow to more than 20  kilograms in size, earning this giant mushroom the title King of Mushrooms. Maitake is so named, not only for its large size but also for its amazing health benefits. Apart from it's health benefits, it is also highly sought after for it's excellent taste.

Beta-Glucans

Medicinal mushroom derived β-glucans are notable for their ability to modulate the immune system. Sources of beta-glucan include various species of mushrooms, such as reishi, shiitake, and maitake. β-Glucans are known as "biological response modifiers" because of their ability to activate the immune system. Immunologists have discovered that receptors on the surface of innate immune cells called dectin-1 and complement receptor 3 (CR3 or CD11b/CD18) are responsible for binding to β-glucans, allowing the immune cells to recognize them.

Maitake MD-Fraction - the original from Japan

Maitake beta-glucan MD-Fraction is the original patented product which is made in Japan to ISO standards.

Maitake Research

A phase I/II human trial, conducted by Memorial Sloan–Kettering Cancer Center, showed Maitake could stimulate the immune system of breast cancer patients. Small experiments with human cancer patients, have shown Maitake can stimulate immune system cells like NK cells. In vitro research has also shown that Maitake can stimulate immune system cells, confirming the clinical experiments in humans.

Small studies with human cancer patients revealed that the Maitake D-fraction portion of the Maitake mushroom possess anti-cancer activity. In vitro research demonstrated that Maitake has potential anti-metastatic properties. In 1997, the US Food and Drug Administration (FDA) approved an Investigational New Drug Application for a portion of the mushroom.

Research has shown Maitake has a hypoglycemic effect, and may be beneficial for the management of diabetes. The reason Maitake lowers blood sugar is due to the fact the mushroom contains a natural alpha glucosidase inhibitor. Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates. Since cancer cells have a preference for glucose, lowering blood sugar levels in cancer patients tends to produce beneficial effects for the patient. Clinical studies in cancer patients with Metformin, a common anti-diabetic drug, show similar beneficial effects.

Maitake contains antioxidants and may partially inhibit the enzyme cyclooxygenase. An experiment showed that an extract of Maitake inhibited angiogenesis via inhibition of the vascular endothelial growth factor (VEGF).

Commonly used treatments used in conjunction with Maitake MD-fraction Mushroom Extract Therapy

GcMAF therapy
Hyperthermia

Cost

Maitake beta-glucan MD-Fraction therapy:

  • 1 month (120 capsules) high-dose 400 mg Maitake MD-Fraction daily
    32,000 yen *

  • DISCOUNT - when ordered with GcMAF Therapy
    1 month (120 capsules) high-dose 400 mg Maitake MD-Fraction daily

    22,000 yen *

* Includes worldwide shipping and handling. Payment is by wire transfer. Contact us to place your order.
* Discount applies if this product is ordered in combination with GcMAF therapy.

Instructions

  • High-dose Maitake MD-Fraction is 400 mg (2 capsules taken twice daily) about 30 minutes before breakfast and dinner.

  • Moderate-dose Maitake MD-Fraction is 200 mg (1 capsule taken twice daily) about 30 minutes before breakfast and dinner.

  • Side effects are not common, but for people who experience some stomach upset, start with a lower dose or take with a small amount of food or at the beginning or end of the meal.

News

Heart Pharmacy website gcmaf.co.jp is now open

Purchase your Colostrum MAF here using PayPal or credit card.

Heart Pharmacy website


2016 Integrative Medical Therapies Conference - Osaka, Japan

Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.

2016 Integrative Medical Therapies conference - Osaka, Japan


Genostics Conference - Sydney, Australia

24-SEP-2016
Dr Toshio Inui

Genostics official website


Symposium on Integrated Medicine: Electric Fields Therapy & Immunotherapy - Jakarta, Indonesia


22-JUL-2016
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.



International Pharmacy Conference

14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.



New New research papers published by Saisei Mirai in Anticancer Research available online.

Research paper
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis (PDF)
ANTICANCER RESEARCH 36: 3771-3774 (2016)

Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis

Research paper
2016 Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields (PDF)
ANTICANCER RESEARCH 36: 3767-3770 (2016)

Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields

Research paper
2016 Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors (PDF)
ANTICANCER RESEARCH 36: 3619-3624 (2016)

Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.

Research paper
2015 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (PDF)
Anticancer Res August 2015 35 (8) 4545-4549

Conference presentation - 10th International Congress for Medical Laser Applications, Germany

13-JUN-2015
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui

Clinical application of Second Generation GcMAF and oral GcMAF
ISLA website

Conference presentation - 9th International Congress for Medical Laser Applications, Germany

29-JUN-2014
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)

Dr Toshio Inui

Dr Toshio Inui Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections

Conference presentation - The 17th Annual Meeting of The Society of Biotherapeutic Approaches, Fukuoka University

7-DEC-2013
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT

Dr Toshio Inui

Dr Toshio Inui Case Report - A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy

New research papers published by Saisei Mirai in Anticancer Research available online.

New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.

Research paper
2013 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity (PDF)
Anticancer Res July 2013 33 (7) 2881-2885

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Research paper
2013 Clinical Experience of Integrative Cancer Immunotherapy with GcMAF (PDF)
Anticancer Res July 2013 33 (7) 2917-2919

Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine Cancer vaccine therapy - autologous tissue derived tumor vaccine

Nature Outlook sponsored article

For more details on GcMAF see our GcMAF page.



Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.

Stability of GcMAF in Serum report Stability of GcMAF in Serum report

The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.

See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.


Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.


University of Tokushima, Institute of Technology and Science, Laboratory Research

Our research group:

References

Deng G, Lin H, Seidman A, et al. (2009). "A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects". Journal of Cancer Research and Clinical Oncology. 135 (9): 1215–21.

Kodama N, Komuta K, Nanba H (2003). "Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients". Journal of Medicinal Food. 6 (4): 371–7.

Kodama N, Komuta K, Sakai N, Nanba H (2002). "Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells". Biological & Pharmaceutical Bulletin. 25 (12): 1647–50.

Kodama N, Asakawa A, Inui A, Masuda Y, Nanba H (2005). "Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa". Oncology Reports. 13 (3): 497–502.

Kodama N, Komuta K, Nanba H (2002). "Can maitake MD-fraction aid cancer patients?". Alternative Medicine Review. 7 (3): 236–9.

Nanba H, Kubo K (1997). "Effect of Maitake D-fraction on cancer prevention". Annals of the New York Academy of Sciences. 833 (1 Cancer): 204–7.

Masuda Y, Murata Y, Hayashi M, Nanba H (2008). "Inhibitory effect of MD-Fraction on tumor metastasis: involvement of NK cell activation and suppression of intercellular adhesion molecule (ICAM)-1 expression in lung vascular endothelial cells". Biological & Pharmaceutical Bulletin. 31 (6): 1104–8.

Konno S, Tortorelis DG, Fullerton SA, Samadi AA, Hettiarachchi J, Tazaki H (2001). "A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients". Diabetic Medicine. 18 (12): 1010.

Hong L, Xun M, Wutong W (2007). "Anti-diabetic effect of an alpha-glucan from fruit body of maitake (Grifola frondosa) on KK-Ay mice". The Journal of Pharmacy and Pharmacology. 59 (4): 575–82.

Kubo K, Aoki H, Nanba H (1994). "Anti-diabetic activity present in the fruit body of Grifola frondosa (Maitake). I". Biological & Pharmaceutical Bulletin. 17 (8): 1106–10.

Lo HC, Hsu TH, Chen CY (2008). "Submerged culture mycelium and broth of Grifola frondosa improve glycemic responses in diabetic rats". The American Journal of Chinese Medicine. 36 (2): 265–85.

Manohar V, Talpur NA, Echard BW, Lieberman S, Preuss HG (2002). "Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice". Diabetes, Obesity & Metabolism. 4 (1): 43–8.

Horio H, Ohtsuru M (2001). "Maitake (Grifola frondosa) improve glucose tolerance of experimental diabetic rats". Journal of Nutritional Science and Vitaminology. 47 (1): 57–63.

Matsuur H, Asakawa C, Kurimoto M, Mizutani J (2002). "Alpha-glucosidase inhibitor from the seeds of balsam pear (Momordica charantia) and the fruit bodies of Grifola frondosa". Bioscience, Biotechnology, and Biochemistry. 66 (7): 1576–8.

Zhang Y, Mills GL, Nair MG (2002). "Cyclooxygenase inhibitory and antioxidant compounds from the mycelia of the edible mushroom Grifola frondosa". Journal of Agricultural and Food Chemistry. 50 (26): 7581–5.

Lee JS, Park BC, Ko YJ, et al. (2008). "Grifola frondosa (maitake mushroom) water extract inhibits vascular endothelial growth factor-induced angiogenesis through inhibition of reactive oxygen species and extracellular signal-regulated kinase phosphorylation". Journal of Medicinal Food. 11 (4): 643–51.

Lin H, She YH, Cassileth BR, Sirotnak F, Cunningham Rundles S. (2004) "Maitake beta-glucan MD-fraction enhances bone marrow colony formation and reduces doxorubicin toxicity in vitro".

Wasser, SP; Weis AL (1999). "Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective". Critical reviews in immunology. (United States: Begell House) 19 (1): 65–96.

Miura, NN; Ohno N, Aketagawa J, Tamura H, Tanaka S, Yadomae T (1996). "Blood clearance of (1-->3)-beta-D-glucan in MRL lpr/lpr mice". FEMS immunology and medical microbiology. (England: Blackwell Publishing) 13 (1): 51–57.

Brown, GD; Gordon, S (2001). "Immune recognition. A new receptor for beta-glucans.". Nature. 413 (6851): 36–7.

Vetvicka, V; Dvorak B, Vetvickova J, Richter J, Krizan J, Sima P, Yvin JC (2007). "Orally administered marine (1-->3)-beta-D-glucan Phycarine stimulates both humoral and cellular immunity". International journal of biological macromolecules. (England: Butterworth-Heinemann) 40 (4): 291–298.


Imagin-K

Contact us
Treatments and therapies
Contact us

Saisei Mirai Clinics
Kobe Saisei Mirai Clinic
  • Cancer
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
Kobe Saisei Mirai Clinic

Boeki Center Building
23rd Floor
5-1-14 Hamabetori Chuo-ku
Kobe-shi
Hyogo-ken 651-0083
Japan


Inui Cancer
Immunotherapy Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
Inui Cancer Immunotherapy Clinic

6-14-17 Kindachou
Moriguchi-shi
Osaka 570-0011
Japan
TEL: +81 (0)6-6902-5251
FAX: +81 (0)6-6902-7133

Inui Cancer Immunotherapy Clinic

Keihan Clinic
  • Cancer
  • Hepatitis
  • Chronic diseases
  • Anti-aging
Saisei Mirai Keihan Clinic

Nature 21 Building
2nd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan
TEL: +81 (0)6-6902-1001


R Future Cancer Int'l Clinic
  • Cancer
R Future Cancer Int'l Clinic

ORE Hiroo Building
7th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


R Science Clinic
  • Skin regeneration
  • Skin rejuvenation
  • Anti-aging
R Mirai Clinic

ORE Hiroo Building
6th Floor
5-10-26 Minamiazabu
Minato-ku
Tokyo-to 106-0047
Japan


Immunotherapy Lab
  • Cell Processing Center
Immunotherapy Lab

Nature 21 Building
3rd Floor
3-34-8 Okubo-cho
Moriguchi-shi
Osaka 570-0012
Japan